Walleye Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Walleye Capital’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$351	Buy	+100	New	+$410	﹤0.01%	4276

Other funds holding IRWD

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Walleye Capital's IRWD Position: Q1 2026 in Review

Walleye Capital reduced its Ironwood Pharmaceuticals (IRWD) stake by 57% in Q1 2026, selling an estimated $1.24M and leaving 225,136 shares worth $790K. The position accounts for ﹤0.01% of the portfolio, ranked #2291.

Walleye Capital first reported a position in IRWD in Q4 2019 and has held it in 9 quarters since. The position peaked at $2.57M in Q4 2024. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

Walleye Capital held 225,136 shares of Ironwood Pharmaceuticals worth $790K as of Q1 2026.
Walleye Capital sold 302,800 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $1.24M.
Ironwood Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2291 holding.
Walleye Capital first reported a position in Ironwood Pharmaceuticals in Q4 2019 and has held it in 9 quarters since.
Walleye Capital's Ironwood Pharmaceuticals position peaked at $2.57M in Q4 2024.
226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.